• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

miRoncol Develops Multi-Cancer Early Detection Blood Test

by Fred Pennic 10/16/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– miRoncol, a medtech startup, has announced the completion of proof-of-concept studies for a groundbreaking multi-cancer early detection blood test. 

– The test utilizes microRNA analysis and machine learning, two technologies recognized by the 2024 Nobel Prizes, to identify cancers at their earliest stages, even before the onset of noticeable symptoms.

The Power of microRNA and Machine Learning

MicroRNAs (miRNAs) are small RNA molecules that play a crucial role in gene regulation. The 2024 Nobel Prize in Physiology or Medicine was awarded to researchers who discovered the fundamental importance of miRNAs in cellular development and disease. Abnormal regulation of miRNAs can contribute to the development of cancer.

miRoncol’s blood test leverages this knowledge by detecting specific miRNAs in the blood and applying a proprietary machine learning algorithm to identify patterns associated with early-stage cancers.

Promising Proof-of-Concept Results

In studies involving over 11,000 blood samples, miRoncol’s multi-cancer early detection model demonstrated impressive accuracy:

  • Broad Cancer Detection: The test detects 12 different cancer types, which account for approximately 60% of all cancer deaths.
  • High Sensitivity: The model exhibits over 90% sensitivity for most of these cancer types, meaning it can correctly identify 90% of actual cancer cases.
  • High Specificity: The test maintains 99% specificity, accurately identifying 99% of individuals without cancer.
  • Early-Stage Detection: The model demonstrates similar performance in detecting early-stage cancers.

Next Steps: Validation and Launch

miRoncol plans to proceed with validation studies to further confirm the test’s accuracy and reliability. The company aims to launch the multi-cancer early detection test from Canada, making it accessible to individuals seeking earlier cancer detection and potentially life-saving interventions.

A Breakthrough in Cancer Diagnostics

miRoncol’s innovative approach represents a significant breakthrough in cancer diagnostics. By harnessing the power of microRNA analysis and machine learning, this blood test has the potential to:

  • Detect Cancers Earlier: Identify cancers at their most treatable stages, before symptoms appear.
  • Improve Patient Outcomes: Enable earlier interventions and potentially increase survival rates.
  • Reduce Healthcare Costs: Decrease the need for costly and invasive diagnostic procedures.
  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Cancer Diagnostics, Oncology

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

M&A:Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

Femtech: Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

Sage Growth Partners Report: Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

EVERSANA and Waltz Health Merge to Redefine Pharmaceutical Commercialization

EVERSANA and Waltz Health Merge to Redefine Pharmaceutical Commercialization

Advancing Diabetes Care: Combating Burnout and Harnessing Technology

Advancing Diabetes Care: Combating Burnout and Harnessing Technology

White House Event Unveils CMS Health Tech Ecosystem Initiative

White House Event Unveils CMS Health Tech Ecosystem Initiative

Meaningful Use Penalties_Meaningful Use_Partial Code Free_Senators Urge CMS to Establish Clear Metrics for ICD-10 Testing

CMS Finalizes TEAM Model: A New Era of Value-Based Surgical Care

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |